Cancer

October 16, 2018
Published by admin_auro at October 16, 2018
Categories

Cancer therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as PDCD4, TIMP3, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 16/October/2018,12.17 pm

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows […]
Do you like it?0
Read more
October 13, 2018
Published by admin_auro at October 13, 2018
Categories

Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1,  p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 13/October/2018, 10.49 am

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different […]
Do you like it?0
Read more
October 13, 2018
Published by admin_auro at October 13, 2018
Categories

Molecular therapy targeting cancer stem cells in chronic myelogenous leukemia (CML) and other metastatic cancers: Misoprostol, an FDA-approved EP4 agonist and abortion-promoting drug, increases the expression of tumor suppressor genes, such as TPM1, CCM3/KRIT1, p53, and TA-p73/p63, targets CML leukemic stem cells, confers protection against CML and prolongs survival, via up-regulation of its target gene, 13/October/2018,10.26 am

Introduction: What they say: A study from the Department of Microbiology and Immunology, Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA shows […]
Do you like it?0
Read more
October 9, 2018
Published by admin_auro at October 9, 2018
Categories

The PD1-PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy in Glioblastoma: A therapeutic mix encompassing Temozolomide, Mevastatin, Cyclabezaprine, Hydralizine, SNX5422, Salinomycin (TMCHSS) inhibits oncoproteins EGFR, and Bcl-xl expression, increases tumor suppressor p53 expression, inhibits glioblastoma proliferation, increases interferon-IFNγ signaling, increase antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 9/October/2018, 12.16 pm

Introduction:What they say: A recent study from Department of Molecular and Medical Pharmacology, David Geffen UCLA School of Medicine, Los Angeles, California, USA; Jonsson Comprehensive Cancer […]
Do you like it?0
Read more
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293
Next page